Health related quality of life (HRQoL) data and utilities derived from preference-based scales are needed for pharmacoeconomic studies. However, available data for hospitalized Medical Oncology patients are scarce or restricted to specific neoplasms. The aim of this work was to obtain health state utilities (HSU) from a heterogeneous population of cancer inpatients admitted to a Medical Oncology department.
Between Dec-15 and March-16, we prospectively collected HRQoL data from consecutive patients admitted to a Medical Oncology ward using EuroQoL 5-domains 5-levels instrument (EQ-5D-5L) and EQ-5D-5L visual analogic scale (VAS). Utility weights were assigned according to Spain social tariff using EuroQol crosswalk value sets. Non-parametric tests (Mann Whitney U, Kruskal-Wallis) were used to evaluate differences of HSU between groups.
215 patients were included; median age: 62 (16-88); ECOG: 1 (45%), 2 (43%), 3-4 (12%); site: lung (27%), breast (15%), colorectal (15%), urogenital (15%); stage: I-II (11%), III (15%), IV (74%); active anticancer treatment: 87%; death during admission: 17 (8%). Mean (SD) EQ-5D-5L HSU for all patients was 0.52 (0.41); VAS: 52 (2). Mean (SD) values for EQ-5D-5L domains: mobility, 2.21 (1.24); self-care, 2.23 (1.49); usual activities, 2.89 (1.41); pain/discomfort, 1.94 (1.29); anxiety/depression: 2.12 (0.94). Differences between groups are shown in Table.Table:
1118P HRQoL values (mean) and differences according to clinical characteristics
|Clinical characteristics||Patients (n = 215)||EQ-5D-5L utility||p||EQ-5D-5L VAS||p|
|ECOG 1 2 3-4||96 92 27||0.77 0.41 0.04|
Average utility (EQ-5D-5L) for Medical Oncology inpatients is 0.52; lowest scores in this population were obtained for pain/discomfort and anxiety/depression domains. Significant differences were observed between different ECOG levels, tumor stages, admission causes and type of treatment.
Clinical trial identification
Legal entity responsible for the study
Francisco Ayala de la Peña
All authors have declared no conflicts of interest.